Industry / Kenya
Malaria Treatment Offers More Benefits
July 2008 | Industry NewsA new study published in The Lancet medical journal demonstrates the growing body of evidence that inexpensive malaria drugs can offer benefits in malaria treatment programmes beyond simply reducing death. The study measured the effects on the health and education of children treated with sulfadoxine-pyrimethamine + amodiaquine (SP + AQ). It found that the prevalence of anaemia was halved in the trial group (6.3%) compared with the placebo group (12.6%) after 12
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
